Humana Missed Mark On Market In Seizure Drug Suit

Law360 (March 11, 2020, 7:22 PM EDT) -- A California federal judge has cut antitrust claims from Humana's suit accusing Mallinckrodt of orchestrating an "outrageous" price-gouging scheme for a hormone gel after finding problems with how the insurer defined the market, but left racketeering and state law claims intact.

U.S. District Judge Dale S. Fischer issued an order Monday rejecting Mallinckrodt's efforts to duck claims under the Racketeer Influenced and Corrupt Organizations Act and state law. But the judge dismissed Humana's Sherman Act claims after finding the company hadn't properly defined the relevant market.

The judge said that while Humana alleges that Acthar is the only adrenocorticotropic hormone, or...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!